Basic Search  |  Summaries  |  Advanced Search

Violation Tracker Individual Record

Company: Par Pharmaceutical Companies Inc.
Current Parent Company: Endo International
Parent at the Time of the Penalty Announcement:  subscribe to see this data field
Recap of Ownership Changes:  subscribe to see this data field
Penalty: $45,000,000
Year: 2013
Date: March 5, 2013
Offense Group: healthcare-related offenses
Primary Offense: off-label or unapproved promotion of medical products
Mega-Scandal: Improper Drug Marketing
Violation Description: New Jersey-based Par Pharmaceutical Companies Inc. pleaded guilty in federal court and agreed to pay $45 million to resolve its criminal and civil liability in the company's promotion of its prescription drug Megace ES for uses not approved as safe and effective by the Food and Drug Administration (FDA) and not covered by federal health care programs.
Level of Government: federal
Action Type: agency action
Agency: Food and Drug Administration referral to the Justice Department
Civil or Criminal Case: civil and criminal
HQ Country of Current Parent: Ireland
Ownership Structure of Current Parent: publicly traded
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: pharmaceuticals
Source of Data: (click here)
Source Notes: If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.
Current parent company note: Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.